Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

News Daily News

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

July 21, 2017

Slimmest Stent to Date Looks Promising in Small Study

News Conference News EuroPCR 2017

Slimmest Stent to Date Looks Promising in Small Study

May 19, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.